New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
close
close
Send us Feedback
Akzo Nobel N.V. (AKZOY)
SUMMARY
BULLS
BEARS
TOPICS
STOCK CHART
SEC FILINGS
Topic Listing for Akzo Nobel N.V.
Accounting Pensions Other Postretirement Benefits
Accounting Stock Issued Employees
Acquisitions Dispositions
Activities 2004
Adverse Stock Market Developments Affect Assets Pension Funds
Age-limit Requirements
Akzo Nobel
Akzo Nobel Announces Intended Sale Organon Biosciences Schering-plough
Akzo Nobel Coatings Chemicals
Akzo Nobel Consolidated Statements Income
Akzo Nobel Listed Dow Jones Sustainability Indexes
Akzo Nobel Listed Ftse4good Index
Akzo Nobel Offer Update Takeover Panel Extension
Akzo Nobel Top Performer Social Responsibility Index
Amendment Articles Association
Antitakeover Provisions Control
Antitrust Cases
Appointment Conflicts Interest
Arnhem Netherlands 2007 Akzo Nobel Announced Today Decided
Arnhem Netherlands 2007 Akzo Nobel Confirms Approached Board
Arnhem Netherlands 2007 Akzo Nobel Confirms Further Indicative
Arnhem Netherlands 2007 Akzo Nobel Euronext Amsterdam Akz
Articles Association Akzo Nobel 2005 English Translation
Asset Retirement Obligations
Assets Liabilities Classified Held Sale
Assets Liabilities Held Sale Organon Biosciences
Associated Companies Joint Ventures
Attestation Report Registered Public Accounting Firm
Audit Committee
Audit Committee Financial Expert
Autonomous Growth
Back Contents
Bad Publicity Damage Brands Adversely Affect Business Results
Base Chemicals
Base Salary
Base Salary 2004
Base Salary 2006
Bases Sources Information
Because Conducts International Operations Exposed Variety Risks Them
Because Organon Depends Sale Limited Number Products Generate
Binding Cash Offer Organon Biosciences Schering-plough
Board Management
Board Practices
Business Combinations
Business Continue Expose Risks Environmental Liabilities
Business Overview
Business Review
Business Review Developments Units
Business Units
Capital Expenditures
Capital Gains
Capital Reduction
Capital Stock
Car Refinishes
Cases
Cash Equivalents
Cash Flows
Certain Trading Activities
Certification Ceo
Certification Ceo 906
Certification Cfo
Certification Cfo 906
Changes Accounting Principles Due Adoption Ifrs
Changes Board Management
Changes Consolidated Interests
Changes Supervisory Board
Chemicals
Chemicals Group
Chemicals New Growth Strategy Paying Off Strong Start
Coatings
Coatings Chemicals
Coatings Excellent Growth Significantly Improved Ebit Margin
Coatings Group
Code Ethics
Collaborations Licensing Agreements
Commitments
Commitments Values
Committees
Commodities
Commoditiy Price Risk Management
Community Program
Compared 2002
Compared 2003
Compensation Remuneration 2006
Conflict Interest
Consent Independent Auditor
Consolidated Statements Other Financial Information
Consolidation
Contractual Obligations
Controls Procedures
Corporate Governance
Corporate Social Responsibility
Costs Expenses
Costs Sales
Court Case Netherlands Pensions
Court Cases
Credit Risk
Credit Risk Management
Critical Accounting Policies
Cumulative Translation Differences
Current Liabilities
Current Taxes
Dealing Disclosure Requirements
Decorative Coatings
Decorative Coatings Europe
Decorative Coatings International
Deferred Income
Deferred Tax Provisions
Deferred Taxes
Defined Benefit Plans
Derivative Financial Instruments
Description Chemicals Business
Description Coatings Business
Description Pharmas Business
Details Irrevocable Undertakings
Developments Coatings Business Units
Diosynth
Diosynth Complex Active Pharmaceutical Ingredients
Directors Senior Management
Discharge Indemnification Members Board Management Supervisory
Disclosure Controls Procedures
Disclosure Table Giving Details Companies Whose Relevant Securities
Discounting
Divestment Unit
Dividend Eur 120 Per Common Share Proposed
Dividend Policy
Dividend Proposal
Dividends
Documents Display
Downgrading Credit Rating Agencies Result Higher Financing Costs
Earnings Nonconsolidated Companies
Earnings Per Share
Ebit
Ebit Margin
Ebit Operating Income Before Incidentals
Ebitda
Editors
Effective Strategy Drives Revenues Growth Net Income
Emission Rights
Employee Benefits
Employee Share Plan
Employees
Employment Agreements
Energy
Engineering
Environmental Matters
Estate Gift Taxes
Estimates
Eur Share Buyback Program
Exchange Controls
Exchange Rate Fluctuations Harmful Impact Financial Results
Exchange Rates Key Currencies
Exemptions Listing Standards Audit Committees
Exhibits
Expenses
Explanation Transition Ifrs
Explanatory Remarks
Face Intense Competition New Products Lower-cost Generic
Failure Complete Sale Organon Biosciences Obs Result Certain
Failure Manage Expansion Effectively Adversely Affect Business
Fair Value Financial Instruments
Financial Condition Results Operations Adversely Affected Not Successfully
Financial Information
Financial Information Consolidated Statements Other
Financial Instruments
Financial Noncurrent Assets
Financing Charges
Financing Charges Net
Financing Income Expenses
Financing Objectives
Foreign Currency Exchange Risk Management
Foreign Exchange Risk Management
Form 20-f
Forward Exchange Contracts
Forward Looking Statement 2005
Forward Looking Statement 2006
Forward Looking Statement 2007
Functional Chemicals
Further Proposal Akzo Nobel Rejected Ici
Gaap
Gains Divestments
General
General Meeting Shareholders
General Meeting Shareholders 2004
Geographic Developments
Government Grants
Government Regulation
Guarantees
Headcount Expansion Emerging Markets Restructuring Mature
Held Maturity Investments
History Development
Human Resources
Ias Fair Value Adjustments
Ifrs
Ifrs Impact 8211 Net Income Shareholders Equity Down
Ifrs Impact Net Income Shareholders Equity Down Funds
Ifrs Standards Prospective Impact
Illustrative Combined Condensed Financial Information Introduction
Impairment Intangible Assets Property Plant Equipment
Impairments
Implementation International Financial Reporting Standards
Inability Access Raw Materials Growth Cost Expenses Petroleum
Incidentals
Incidentals Balance Gain Eur
Incidentals Net Gain Eur 221
Income Tax Receivable Payable
Income Taxes
Indemnification Members Board Management Supervisory
Index
Inducement Fee
Industrial Activities
Industrial Finishes
Industry Segment Information
Industry Segment Information Geographic Data
Information Financial Instruments
Insurance
Intangible Assets
Intellectual Property
Inter Alia
Interest Rate Derivatives
Interest Rate Risk Management
Interest Risk Management
Interim Dividend Unchanged Eur 030
Internal Control Integrated Framework
Internal Control-integrated Framework
Internal Risks
Intervet
Intervet Solid Performance
Intervet Veterinary Products
Introduction
Inventories
Inventory Costs Amendment Arb Chapter
Invested Capital
Investment Associates
Jointly Controlled Companies
Key Figures
Leases
Legal Antitrust Environmental Cases
Legal Proceedings
Liquidation Rights
Liquidity Capital Resources
Long-term Borrowings
Long-term Borrowings Short-term Debt
Long-term Incentives
Long-term Incentives 2006
Lower Cash Position Due Share Buyback Program
Major Shareholders
Major Shareholders Related Party Transactions
Management Change Not Adequate Possibly Lead Failure Attract
Managements Annual Report Internal Control Over Financial Reporting
Marine Protective Coatings
Marketing Distribution
Markets
Material Contracts
Memorandum Articles Association
Movements
Moving Average Roi
Nature Forward-looking Statements Involve Risk Uncertainty Because They
Net Financing Charges
Net Income
Net Income Down
Net Income Lower Major Influence One-off
Net Interest-bearing Borrowings
Netherlands Taxation
New Accounting Pronouncements
New Pension Scheme Netherlands
New Strategic Focus
Nobilas
Nobilas Accident Management Services Been Transferred Coatings Other
Nobilas Claims Fleet Solutions
Nobilon
Nomination Committee
Nonconsolidated Companies
Nonconsolidated Flexsys
Nonrecurring
Not Able Identify Future Acquisitions Successful Integrating Acquired
Not Able Identify Significant Technology Improvements Future Acquisitions
Not Publication Information
Notes
Number Employees
Nurturing Talent
Off-balance Sheet Transactions
Offer Listing
Offer Listing Details
Offer Period Otherwise Ends Persons Act Together Pursuant
One-off
Operating Income
Operational Cash Flow Lower Due Higher Working Capital
Operational Income
Operational Performance
Organizational Structure
Organon
Organon Biosciences
Organon Figures Now Also Include Results Former Diosynth
Organon Intervet
Organon Prescription Drugs
Other
Other Adjustments
Other Employee Benefits
Other Financial Noncurrent Assets
Other Financial Noncurrent Assets Available Sale
Other Investigations Litigation
Other Litigation
Other Long-term Employee Benefits
Other Operating Income
Other Operating Income Expenses
Other Principles Observed Preparation Statement Income
Other Provisions
Other Results
Outcome Tax Disputes Litigation Indemnification Guarantees Regulatory Action
Outlook
Outlook Unchanged
Overview
Part
Pensions
Pensions Other Postretirement Benefits
Percent Total Net Sales Operating Income
Percent Total Revenues Operating Income
Performance Development Dialog
Performance Share Plan Board Management
Pfizer Payment
Pharma
Pharma Group
Planet
Polymer Chemicals
Powder Coatings
Preemptive Rights
Present Operations Exclude Chemicals Businesses Divested 2004 Incidentals
Presentation Ifrs-based Information
Price Controls
Principal Accountant Fee Services
Principal Objects
Principles
Principles Determination Income
Principles Valuation Assets Liabilities
Product Liability Claims Adversely Affect Business Results Operations
Product Regulation Adversely Affect Ability Bring New Products
Property Plant Equipment
Provisions
Provisions Environmental Costs
Provisions Restructuring Activities
Pulp Paper Chemicals
Pursuant Private Securities Litigation Reform Act 1995
Receivables
Reconciliation Equity
Regulations Limit Prices Charge Pharmaceutical Products Reduce Revenues
Related Party Transactions
Relations Shareholders Other Investors
Remuneration
Remuneration 2004
Remuneration 2005
Remuneration Committee
Remuneration Committee Nomination
Remuneration Policy
Remuneration Policy 2005
Remuneration Structure 2004
Report 2005 Auditors
Report 2007
Report 4th Key Figures
Report Independent Registered Public Accounting Firm
Research Costs Preparation Start-up Expenses
Research Development
Research Development Efforts Not Succeed Competitors Develop Effective
Research Development Patents Licenses
Responsible Liabilities Arising Out Antitrust Litigation
Responsible Liabilities Arising Out Non-compliance Laws Regulation Antitrust
Restructuring Activities
Restructuring Impairment Charges
Restructuring Provisions
Results Divestments
Revenue Recognition
Revenue Recognition Financial Statements
Revenue Recognition Financial Statements-frequently Asked Questions Answers
Revenues
Revenues 2005 Eur 1094 2004 1027
Revenues 2005 Eur 2425 2004 2344
Revenues 2006 Eur 1125 2005 1094
Revenues 2006 Eur 1129 2005 975
Revenues 2006 Eur 1959 2005 1740
Revenues 2006 Eur 2287 2005 2038
Revenues 2006 Eur 516 2005 471
Revenues 2006 Eur 523 2005 511
Revenues 2006 Eur 740 2005 703
Revenues 2006 Eur 767 2005 787
Revenues 2006 Eur 922 2005 886
Revenues 2006 Eur 966 2005 893
Revenues Autonomous Growth
Revenues Cost Income
Revenues Operating Income Activities
Risk Factors
Risks Production Processes Adversely Affect Results Operations
Role Society
Rules Procedure Codes Conduct Complaints Procedures
Safe Harbor Statement
Salaries Wages Social Charges
Sales
Sales 2004 Eur 1024 2003 1010
Sales 2004 Eur 1592 2003 1489
Sales 2004 Eur 175 2003 171
Sales 2004 Eur 1911 2003 1842
Sales 2004 Eur 2010 2003 2273
Sales 2004 Eur 274 2003 267
Sales 2004 Eur 366 2003 479
Sales 2004 Eur 494 2003 492
Sales 2004 Eur 575 2003 544
Sales 2004 Eur 613 2003 604
Sales 2004 Eur 863 2003 858
Sales 2004 Eur 875 2003 832
Sales 2004 Eur 927 2003 880
Sales 2004 Eur 980 2003 1008
Sales Cost Income
Sales Operating Income Activities
Salt
Schedule Valuation Qualifying Accounts
Scheme Document Other Related Jurisdiction Outside Netherlands Inform
Seasonality Adversely Affect Operating Results Coatings Chemicals Business
Segment Reporting
Sensitivity Analysis
Separation Pharma Business Track
Share Ownership
Share Profit Associates
Share-based Compensation
Share-based Payments
Shareholders
Shareholders Equity
Shares Akzo Nobel Held Members Supervisory Board Management
Short-term Borrowings
Short-term Employee Benefits
Short-term Incentive Annual Bonus
Short-term Incentive Annual Bonus 2006
Signatures
Significant Changes
Sources Availability Raw Materials
Special Benefits
Statutory Other Reserves
Statutory Reserves
Stock Options Performance-related Shares
Stock-based Compensation
Strategic Decision Making Risks
Strategy
Strong Cash Flow Generated Operating Activities Eur
Strong Financial Position
Subscribed Share Capital
Subsequent Events
Subsidiaries Associated Companies
Summary Significant Accounting Policies Used Preparing Consolidated Financial
Summary Significant Differences Between Dutch Corporate Governance Practices
Supervisory Board
Supervisory Board Activities
Supplemental Cash Flow Disclosures
Surface Chemistry
Surfactants
Table Contents
Tax
Tax Rate
Taxation Capital Gains
Taxation Dividends
Taxes
Technology Engineering
Top-line Record Net Income Eur 115
Topline Growing Operational Results Lower
Trade Other Payables
Trade Other Receivables
Trading Conditions
Trading Conditions 2006
Translation Foreign Currencies
Treasury Shares
Unable Retain Key Personnel Attract New Adverse Effect
Understanding Whether Formal Informal Acquire Interest Relevant Securities
Undertakings Implement Scheme
United States Taxation
Valuation
Velperweg 6824 Arnhem
Velperweg 6824 Arnhem Netherlands Address Principal Executive Offices
Voting Rights
Withholding Tax
Workforce 1040 Organic Growth Acquisitions Partially Offset Divestments
Workforce 1100 Organic Growth Acquisitions Partially Offset Divestments
Workforce Balance 150
Workforce Down 680 Due Restructurings
Bet you've never seen portfolio analytics like these.
Introducing
SigFig
— from the creators of
Take Tour